Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (23530)	7/26/1998 9:33:00 AM
From: Robet Butkus	Respond to of 32384

Keep those emails coming folks...

To: Skeeter Bug who wrote (23530)	7/26/1998 1:59:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< please provide a quick synopsis of the situation. >> LGNDW are getting very cheap, IMHO. They are down to a bid of $5 1/4. Skeets, I have no idea what is happening to LGND. They've got two NDAs in front of the FDA, and three more on the way. Here's something that could impact LGND's stock, and other biotech stocks: The FDA will issue new regulations in the near future: - An expansion of the fast-track program for life threatening diseases, such as cancer and AIDS, making for quicker FDA action. This couldn't come at a better time, what with two LGND NDAs in front of the FDA! - Approved drugs will be allowed for treating non-approved illnesses by providing info to doctors. This is the "off-label" use that's been discussed here. Hmmmmmm!? I thought that was already implemented. I guess not! - Faster approval of low risk medical devices by having private groups doing the approval process. Good luck, Bob